首页> 美国卫生研究院文献>other >p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy

【2h】

p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy

机译：在p53疫苗和吉西他滨化疗后p53反应性T细胞与铂耐药性上皮性卵巢癌患者的临床获益相关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PURPOSETo conduct a Phase I trial of a Modified Vaccinia Ankara vaccine delivering wild type human p53 (p53MVA) in combination with gemcitabine chemotherapy in patients with platinum-resistant ovarian cancer.

机译：目的进行改良的痘苗安卡拉疫苗的第一阶段试验，该疫苗可将野生型人p53（p53MVA）与吉西他滨化学疗法联合治疗对铂类耐药的卵巢癌患者。

著录项

期刊名称 other
作者
Nicola R Hardwick; Paul Frankel; Christopher Ruel; Julie Kilpatrick; Weimin Tsai; Ferdynand Kos; Teodora Kaltcheva; Lucille Leong; Robert Morgan; Vincent Chung; Raechelle Tinsley; Melissa Eng; Sharon Wilczynski; Joshua D I Ellenhorn; Don J Diamond; Mihaela Cristea;
展开▼
作者单位

展开▼
年(卷),期 -1(24),6
年度 -1
页码 1315–1325
总页数 22
原文格式 PDF
正文语种
中图分类
关键词
immunotherapy p53 clinical trial ovarian cancer gemcitabine;

机译：免疫疗法;p53;临床试验;卵巢癌;吉西他滨;

相似文献

外文文献
中文文献
专利

1. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy [J] . Nicola R. Hardwick, Paul Frankel, Christopher Ruel, Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第6期

机译：用P53疫苗和吉西他滨化疗治疗后，P53-活性T细胞与铂抗性上皮性卵巢癌患者的临床益处相关。
2. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients [J] . SafraT., AsnaN., VeizmanA., Anti-cancer drugs . 2014,第3期

机译：吉西他滨和卡铂的组合在治疗铂耐药和铂敏感的复发性上皮性卵巢癌患者中显示出相似的疗效
3. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. [J] . Gadducci A, Di Cristofano C, Zavaglia M, Anticancer Research: International Journal of Cancer Research and Treatment . 2006,第1B期

机译：晚期浆液性上皮性卵巢癌患者P53基因状态与对紫杉醇加铂类化学疗法的反应及长期临床疗效相关。
4. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. A phase 1/2 study combining gemcitabine Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer [O] . Eveline M. Dijkgraaf, Saskia J.A.M. Santegoets, An K.L. Reyners, 2015

机译：吉西他滨培根创和p53 SLP疫苗联合治疗铂耐药性卵巢癌的1/2期研究
7. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy [O] . Nicola R. Hardwick, Paul Frankel, Christopher Ruel, 2018

机译：用P53疫苗和吉西他滨化疗治疗后，P53-活性T细胞与铂抗性上皮性卵巢癌患者的临床益处相关。

p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅